AI Could Reshape Clinical Trials—and the Business of Pharma
TIME’s flagship AI newsletter spotlighted Formation Bio CEO Ben Liu and the company’s contrarian approach to AI in pharma. While much of the industry has focused on using AI for drug discovery, the piece highlights how Formation Bio is tackling the real bottleneck: clinical trials.
The feature positions Formation Bio’s model as a new kind of pharma company, one that acquires promising drug candidates and uses AI to accelerate the administrative and operational work of trials, from patient recruitment to regulatory filings. The article notes the company’s claim of reducing trial timelines by as much as 50%, and details two successful drug sales, including a deal with Sanofi and another involving Eli Lilly.
Liu’s vision for a leaner, AI-powered pharma company comes through clearly: fewer people, faster trials, and ultimately more accessible medicines for patients.
